Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
复制标题
DOI：
10.1093/jnci/92.22.1823
复制
发表时间：
2000-11-15
影响因子：
10.3
通讯作者：
Carpenter, L
中科院分区：
文献类型：
--
作者：
Appleby, P;Beral, V;Carpenter, L
背景：感染人类免疫缺陷病毒 1 (HIV) 的人患卡波西肉瘤和非霍奇金淋巴瘤的风险会增加。大约自1997年以来，高效抗逆转录病毒疗法（HAART）已在北美、欧洲和澳大利亚的HIV感染者中广泛使用。获得性免疫缺陷综合征（AIDS）的发病率和死亡率随着HAART的使用而显着下降，但其对HIV感染者癌症发病率的影响尚不清楚。方法。对来自 23 项前瞻性研究（包括来自北美、欧洲和澳大利亚的 47936 名 HIV 血清阳性个体）的癌症发病率数据进行了集中整理、检查和分析。计算了卡波西肉瘤、非霍奇金淋巴瘤、霍奇金病、宫颈癌和 20 种其他癌症类型或部位的调整后发病率（以每 1000 人年的癌症数量表示）。在对研究、年龄、性别和 HIV 传播进行调整后，将 1997 年至 1999 年的发病率与 1992 年至 1996 年的发病率进行比较，估计比率。组。所有统计检验都是双面的。结果：从1992年到1999年期间，在138148人年的观察中报告了2702例癌症，其中90%以上是卡波西肉瘤或非霍奇金淋巴瘤。卡波西肉瘤的调整后发病率从 1992 年至 1996 年的 15.2 下降至 1997 年至 1999 年的 4.9（比率 = 0.32；99% 置信区间 [CI] = 0.26-0.40；分别基于 1489 例和 190 例病例；P
Background: The risk of Kaposi's sarcoma and non-Hodgkin's lymphoma is increased in people infected with the human immunodeficiency virus-1 (HIV). Highly active antiretroviral therapy (HAART) has been widely used by HIV-infected people in North America, Europe, and Australia since about 1997, Acquired immunodeficiency syndrome (AIDS) incidence and mortality rates have fallen markedly in association with the use of HAART, but its impact on the incidence of cancer in HIV-infected people is less clear. Methods. Cancer incidence data from 23 prospective studies that included 47936 HIV-seropositive individuals from North America, Europe, and Australia were collated, checked, and analyzed centrally. Adjusted incidence rates (expressed as number of cancers per 1000 person-years) for Kaposi's sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, cervical cancer, and 20 other cancer types or sites were calculated, Rate ratios were estimated, comparing incidence rates from 1997 through 1999 with rates from 1992 through 1996, after adjustment for study, age, sex, and HIV transmission group. All statistical tests were two-sided. Results: For the period from 1992 through 1999, 2702 incident cancers were reported in 138148 person-years of observation, and more than 90% of them were either Kaposi's sarcoma or non-Hodgkin's lymphoma. The adjusted incidence rate for Kaposi's sarcoma declined from 15.2 in 1992 through 1996 to 4.9 in 1997 through 1999 (rate ratio = 0.32; 99% confidence interval [CI] = 0.26-0.40; based on 1489 and 190 cases, respectively; P